Cargando…

Evaluating cost benefits of combination therapies for advanced melanoma

BACKGROUND: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 months. Recently, combination targeted therapies have i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Ivar S., Zacherle, Emily, Blanchette, Christopher M., Zhang, Jie, Yin, Wes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Just Medical Media Limited 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974051/ https://www.ncbi.nlm.nih.gov/pubmed/27540409 http://dx.doi.org/10.7573/dic.212297

Ejemplares similares

One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States
por: Blanchette, Christopher M., et al.
Publicado: (2017)

Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.
por: Blanchette, Christopher M., et al.
Publicado: (2017)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
por: Özdemir, Dilay, et al.
Publicado: (2023)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma
por: Stoian, Alexandru-Rares, et al.
Publicado: (2023)

Cost-benefit parameters in evaluating automation
por: Craig, Thomas M.
Publicado: (1983)

Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence
por: Voskoboynik, Mark, et al.
Publicado: (2014)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
por: Dalal, Anand A, et al.
Publicado: (2011)

Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis
por: Wu, Shuang, et al.
Publicado: (2021)

Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wei, et al.
Publicado: (2020)

Updates in Therapy for Advanced Melanoma
por: Singh, Bhavana P., et al.
Publicado: (2016)

Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review
por: Copley-Merriman, Catherine, et al.
Publicado: (2018)

The Costs and Benefits of Animal Experiments: An Evaluation with Bias
por: Prankel, Susanne
Publicado: (2012)

Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
por: Srivastava, Neeharika, et al.
Publicado: (2014)

Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis
por: Bandari, Daniel S., et al.
Publicado: (2012)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis
por: An, Qing, et al.
Publicado: (2019)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2022)

The emergence of neoadjuvant therapy in advanced melanoma
por: Sun, James, et al.
Publicado: (2019)

Cost-Effectiveness of Proton Beam Therapy for Intraocular Melanoma
por: Moriarty, James P., et al.
Publicado: (2015)

Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
por: Li, Si Ni, et al.
Publicado: (2023)

Advancements in Radiographic Evaluation Through the Migration into NDE 4.0
por: Saboonchi, Hossain, et al.
Publicado: (2021)

Nanoparticle-Based Combination Therapy for Melanoma
por: Chen, Hongbo, et al.
Publicado: (2022)

A novel combined method for cost–benefit production of DNA ladders
por: Mostaan, Saied, et al.
Publicado: (2015)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?
por: Bari, Shahla, et al.
Publicado: (2022)

Costs and benefits of awns
por: Guo, Zifeng, et al.
Publicado: (2016)

Gene therapy for spinal muscular atrophy: the benefit–cost profile
Publicado: (2021)

Intralesional therapy for advanced melanoma: promise and limitation
por: Agarwala, Sanjiv S.
Publicado: (2015)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

Neoadjuvant therapy of locally/regionally advanced melanoma
por: Khunger, Arjun, et al.
Publicado: (2019)

Advances in targeted therapy and immunotherapy for melanoma (Review)
por: Qin, Ziyao, et al.
Publicado: (2023)

Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective
por: Huang, Ying, et al.
Publicado: (2014)

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis
por: Walsh, Jessica A., et al.
Publicado: (2023)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tpfs51d6bb648ncefc0h4tdg2e